UPDATE
: Wednesday, December 11, 2019
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
기사
(전체 478건)
제목보기
제목보기
제목+내용
기사보기
Aprogen, 1st Korean biotech firm to win unicorn status
Aprogen has joined the l...
Jeong Sae-im
|
2019-12-11 13:10
기사보기
Samsung Bioepis to start P3 trial for Ontruzant in China
Samsung Bioepis said tha...
Lee Han-soo
|
2019-12-10 14:16
기사보기
Samsung execs get jail term for destroying evidence
A Seoul court gave jail ...
Jeong Sae-im
|
2019-12-10 11:43
기사보기
Celltrion unveils long-term P3 trial results for Truxima in US
Celltrion said that it h...
Lee Han-soo
|
2019-12-09 10:36
기사보기
Celltrion 1st Korean biopharmaceutical firm to achieve $1-billion exports
Celltrion Healthcare sai...
Lee Han-soo
|
2019-12-05 15:04
기사보기
Alteogen inks licensing-out deal for SC injection formulation technology
Alteogen, a biotech firm...
Jeong Sae-im
|
2019-12-02 15:25
기사보기
Kolon Life Science’s research head arrested for false Invossa data
A Seoul court issued an ...
Jeong Sae-im
|
2019-11-28 11:18
기사보기
FDA begins to review Samsung Bioepis' anticancer biosimilar application
Samsung Bioepis headquar...
Lee Han-soo
|
2019-11-20 15:10
기사보기
Vivozon’s acquisition of Lumimicro may aim at backdoor listing
Vivozon, a privately hel...
Jeong Sae-im
|
2019-11-20 14:44
기사보기
ABL Bio, Genscript to cooperate on bispecific antibodies
ABL Bio said that it wou...
Lee Han-soo
|
2019-11-19 17:18
기사보기
Will Biogen be 1st to get FDA nod for Alzheimer’s drug?
Biogen recently unveiled...
Kim Yun-mi
|
2019-11-14 11:23
기사보기
How can Korean drugmakers enter Europe successfully?
Officials from the Korea...
Jeong Sae-im
|
2019-11-13 15:22
-
1
2
3
4
5
6
7
8
9
10
다음
-
Back to Top